( 2008 ) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells . Blood , 112 , 2390 – 2399 .Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, ...
We stained for (1) HLA-DRB1 using anti-HLA-DRB1 antibody followed by oligonucleotide-conjugated PLA secondary antibody (2° Ab) (+) and (2) fucosylated glycan using biotinylated (‘B’) AAL lectin followed by anti-biotin antibody followed by oligonucleotide-conjugated PLA secondary (−). ...
The proteins were co-immunoprecipited with His-tagged antibody from the lysate of cells with transfected MEST cDNA or MEST mut plasmid. The MEST stably interacted with eIF4E2; whereas this interaction was reduced in MEST mut group, suggesting that LeY on MEST determined the interaction of MEST...
Fig. 2: IgG1 and IgG3 dominate antibody response to PfEMP1. aCorrelation between GLURP- or HB3VAR06-specific IgG levels and age. Spearman’s rank correlation (rs) and p values are shown.bSpecific IgG levels against recombinant GLURP and HB3VAR06 in plasma samples from children (n =...
Further, complex fucosylation containing glycan structure sialyl-Lewis x (sLex) was stained using α-CD15s monoclonal antibody (clone CSLEX1; BD Biosciences, San Jose, CA; 1:500 dilution). In addition to 95–100 PMP specimens, all the proteins and sLex glycan were further immunostained from ...
Moreover, core fucosylation is also related to antibody-dependent cellular cytotoxicity, and removal of immunoglobulin G1 in its Fc region can significantly increase antibody-dependent cellular cytotoxicity24,25,26. Therefore, establishing a robust method for characterizing site-specific core fucosylation ...
et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-Type Oligosaccharides Shows the Critical Role of Enhancing Antibody-Dependent Cellular Cytotoxicity”, The Journal of Biological Chemistry 278(5):3466-3473 (Jan. 2003). Smith...
thus reducing side effects. A drug could be attached by a linker that would release the cytotoxin in the vicinity of the target tumor cell, creating a locally high concentration at the tumor, or it could remain attached to the antibody until the antibody was internalized after binding to a ...
The present invention relates to the field of cancer therapy using anti-cancer antibody. Exhibit toxic improved side effect profile and anti-cancer efficacy, glycosylation characteristic is improved, in particular, medical uses of the anti-EGFR antibody fucosylation is reduced is provided. An anti-...
Previously, we reported a novel class of bispecific molecules targeting the antibody Fc region and folate receptor, named Fc-binding antibody-recruiting molecules (Fc-ARMs). Fc-ARMs can theoretically recruit most endogenous antibodies, inducing cancer cell elimination via antibody-dependent cell-mediated...